While women are equally or overrepresented in clinical trials for hypertension, atrial fibrillation (AFib) and pulmonary arterial hypertension, they are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome, according to a new study published in the Journal of the American College of Cardiology.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.

The American Heart Association (AHA)/American Stroke Association (ASA) is revisiting its recently updated stroke guidelines after issuing a “correction” that removed several portions.

A new nationwide study from Japan highlighted the importance of timely ambulance arrival, showing that bystander defibrillation and cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest are essentially worthless if EMS response times are slower than 13 minutes and 11 minutes, respectively.

Common therapies used in the treatment of psoriasis may help reduce coronary plaque, according to a new study presented April 26 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego.

Alteplase is sometimes administered to dissolve clots before endovascular thrombectomy in patients with ischemic stroke. But a new study in the New England Journal of Medicine demonstrates tenecteplase, a genetically modified form of alteplase, is associated with better blood flow restoration and improved functional outcomes.

A new device allows clinicians to remove blood clots from the pulmonary arteries and improve right ventricular function without the use of thrombolytics, according to a late-breaking clinical study presented April 26 at SCAI 2018 in San Diego.